Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination

Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Amal, Al-Mulla, Mohammad R., Abubaker, Jehad, Al-Mulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459929/
https://www.ncbi.nlm.nih.gov/pubmed/34543154
http://dx.doi.org/10.1080/21645515.2021.1969855
Descripción
Sumario:Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8(+)T-cell immunity.

Ejemplares similares